ClinicalTrials.gg
Enrolling by invitationNCT04987229Updated Aug 14, 2026

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

A Phase 3 interventional study of OLZ/SAM in Bipolar I Disorder and Schizophrenia, sponsored by Alkermes, Inc.. Enrolling by invitation at 35 sites in 5 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
236
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies in Schizophrenia by Alkermes, Inc. — 2 open to participants now, 2 under way, 2 of them phase 3. Schizophrenia · Alkermes, Inc..

Planned enrollment
12th of 19
236 · median 281
Started
2021
the only one that year
Phase 3
12 of 21
2 open now
Registered
19th of 21
by date

Among the 21 studies in Schizophrenia by Alkermes, Inc., this one is the 12th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is one of 12 in phase 3, and was the 19th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 21 studies in Schizophrenia by Alkermes, Inc. are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Schizophrenia by Alkermes, Inc., or all of them as a file.
02

Study summary

To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder

03

Conditions studied

  • Bipolar I Disorder
  • Schizophrenia

Browse trials for

Keywords

  • Bipolar I Disorder
  • Schizophrenia
  • Samidorphan
  • Pediatric
  • Olzanzapine
  • Safety
  • LYBALVI
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has completed the treatment period in either the ALKS 3831-A311 or the ALKS 3831-A312 study within 10 days of enrolling into this extension study, or subject had terminated early from Study ALKS 3831-A312 due to the weight gain criterion.
  • Subject will benefit from continued therapy with OLZ/SAM per clinical judgment.
  • Subject is able to be treated on an outpatient basis.
  • Subject must not be a danger to self or others (per Investigator judgement) and has family support available to be maintained as an outpatient.
  • Subject's parent(s)/legal guardian(s) is considered reliable by the Investigator and has agreed to provide support to the subject to ensure compliance with study treatment, visits, and protocol procedures.
  • Subject agrees to abide by the requirements specified in the protocol for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Subject poses a current suicide risk as assessed by the Investigator or as confirmed by the baseline Columbia-Suicide Severity Rating Scale by a response of "Yes" to question numbers 4 or 5 with ideation or suicidal behavior since the last visit.
  • Subject has any finding that in the view of the Investigator or Medical Monitor would compromise the safety of the subject or affect their ability to fulfill the protocol visit schedule or visit requirement.
  • Subject is currently taking medications that are with olanzapine use or exhibit drug-interaction potential with olanzapine
  • Subject has a positive test for opioids.
  • Subject has a positive urine pregnancy test, is currently pregnant or breastfeeding, or plans to become pregnant or begin breastfeeding at any point during the study and for 90 days after any study drug administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    All subjects

    All subjects will receive OLZ/SAM at a dose determined by the Investigator and based on the olanzapine dosing received in the antecedent study (ALKS 3831-A311 or ALKS 3831-A312 ENLIGHTEN-Youth)

    Drug: OLZ/SAM

Interventions

  • DrugOLZ/SAM

    Drug page: S-Adenosylmethionine

    Olanzapine and Samidorphan fixed dose coated tablet taken once daily

    Also known as: ALKS 3831

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: Up to 52 weeks

07

Study locations

35 sites
  • Alkermes Investigational Site
    Dothan, Alabama 36303, United States
  • Alkermes Investigational Site
    Little Rock, Arkansas 72204, United States
  • Alkermes Investigational Site
    Stanford, California 94305, United States
  • Alkermes Investigational Site
    Washington D.C., District of Columbia 20010, United States
  • Alkermes Investigational Site
    Miami Lakes, Florida 33016, United States
  • Alkermes Investigational Site
    Decatur, Georgia 30030, United States
  • Alkermes Investigational Site
    Chicago, Illinois 60611, United States
  • Alkermes Investigational Site
    Indianapolis, Indiana 46202, United States
  • Alkermes Investigational Site
    Saint Charles, Missouri 63304, United States
  • Alkermes Investigational Site
    Lincoln, Nebraska 68526, United States
  • Alkermes Investigator Site
    New York, New York 10016, United States
  • Alkermes Investigational Site
    Cincinnati, Ohio 45229, United States
  • Alkermes Investigational Site
    West Chester, Ohio 45069, United States
  • Alkermes Investigational Site
    Richmond, Virginia 23220, United States
  • Alkermes Investigational Site
    Everett, Washington 98201, United States
  • Alkermes Investigational Site
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1181ACH, Argentina
  • Alkermes Investigational Site
    La Plata, Buenos Aires 1900, Argentina
  • Alkermes Investigational Site
    Buenos Aires, Buenos Aires F.D. C1133AAH, Argentina
  • Alkermes Investigational Site
    Mendoza, Mendoza Province 5500, Argentina
  • Alkermes Investigational Site
    Córdoba, X5003DCE, Argentina
  • Alkermes Investigational Site
    Fortaleza, Ceará 60430-140, Brazil
  • Alkermes Investigational Site
    Curitiba, Paraná 80240-280, Brazil
  • Alkermes Investigational Site
    Rio de Janeiro, Rio de Janeiro 22270-060, Brazil
  • Alkermes Investigational Site
    São Paulo, São Paulo 05403-010, Brazil
  • Alkermes Investigational Site
    Goiânia, 74093-040, Brazil
  • Alkermes Investigational Site
    São Paulo, 01228-000, Brazil
  • Alkermes Investigational Site
    Barranquilla, 110121, Colombia
  • Alkermes Investigational Site
    Bello, 51053, Colombia
  • Alkermes Investigational Site
    Bogotá, 80020, Colombia
  • Alkermes Investigational Site
    Pereira, 660003, Colombia
  • Alkermes Investigational Site
    León, Guanajuato 37000, Mexico
  • Alkermes Investigational Site
    Monterrey, Nuevo León 64620, Mexico
  • Alkermes Investigational Site
    Monterrey, Nuevo León 64710, Mexico
  • Alkermes Investigational Site
    Culiacán, Sinaloa 80230, Mexico
  • Alkermes Investigational Site
    Gustavo A. Madero, State of Mexico C.P. 07000, Mexico
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Sep 2027, 71 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 71 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2021
First posted
Aug 3, 2021
StartActual
Oct 22, 2021
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04987229
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Aug 3, 2021
Start date
Oct 22, 2021
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

David McDonnell, MD
study director · Alkermes, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: S-Adenosylmethionine

Start the discussion